Generic Biologics Bill’s Key Battleground May Be Senate Health Committee
Executive Summary
Legislation to create a pathway for FDA approval of generic biologics should be attached to the reauthorization of the Prescription Drug User Fee Act, Sen. Charles Schumer, D-N.Y., said at a Feb. 14 press conference announcing reintroduction of the bill
You may also be interested in...
Waxman To Seek Consensus On FOBs, Incentives For Early Patent Resolution
Efforts will be made "over the next few months" to bring House Energy and Commerce Committee members to a consensus on a follow-on biologics bill, according to committee staffer Ann Witt
Waxman To Seek Consensus On FOBs, Incentives For Early Patent Resolution
Efforts will be made "over the next few months" to bring House Energy and Commerce Committee members to a consensus on a follow-on biologics bill, according to committee staffer Ann Witt
Biosimilar Competition Debate: Must Products Be Interchangable To Generate Savings?
FTC hears arguments on whether the number of competitors, or their pharmacy-level substitutability, drives prices lower.